Mechanisms underlying iron and copper ions toxicity in biological systems: Pro-oxidant activity and protein-binding effects

Chemico-Biological Interactions

Volumn 188, Issue 1, 2010, Pages 220-227

  Letelier, María Eugenia ^a   Sánchez Jofré, Sebastián ^a   Peredo Silva, Liliana ^a   Cortés Troncoso, Juan ^a   Aracena Parks, Paula ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Catechin; Copper; Iron; Lipid peroxidation; N Acetylcysteine; Thiol proteins

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; CATECHIN; COPPER ION; FERRIC ION; GLUTATHIONE TRANSFERASE; THIOL GROUP; COPPER; GLUTATHIONE PEROXIDASE; IRON; OXIDIZING AGENT; PROTEIN;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; COPPER METABOLISM; ENZYME INHIBITION; IRON METABOLISM; LIPID PEROXIDATION; LIVER CYTOSOL; LIVER MICROSOME; MALE; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PROTEIN BINDING; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; SPRAGUE DAWLEY RAT; TOXICITY;

ACETYLCYSTEINE; ANIMALS; CATECHIN; COPPER; GLUTATHIONE PEROXIDASE; IRON; LIPID PEROXIDATION; MALE; OXIDANTS; PROTEINS; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 77956179036     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.06.013     Document Type: Article

References (35)

1. Anderson G.J., Vulpe C.D. Mammalian iron transport. Cell. Mol. Life Sci. 2009, 66(20):3241-3261.
2. Kaplan J.H., Lutsenko S. Copper transport in mammalian cells: special care for a metal with special needs. J. Biol. Chem. 2009, 284(38):25461-25465.
3. Arredondo M., Nunez M.T. Iron and copper metabolism. Mol. Aspects Med. 2005, 26(4-5):313-327.
4. Linder M.C., Hazegh-Azam M. Copper biochemistry and molecular biology. Am. J. Clin. Nutr. 1996, 63(5):797S-811S.
5. Zimmermann M.B., Hurrell R.F. Nutritional iron deficiency. Lancet 2007, 370(9586):511-520.
6. Halliwell B. Biochemistry of oxidative stress. Biochem. Soc. Trans. 2007, 35(Pt. 5):1147-1150.
7. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 2007, Oxford University Press, Oxford/New York.
8. Ginder G.D. Microcytic and hemochromic anemias. Cecil Medicine 2008, Saunders Elsevier, Philadelphia, PA. L. Goldman, D.A. Aussiello, W. Arend, J.O. Armitage, D. Clemmons, J. Drazen, R. Griggs, J. Newman, E. Foster (Eds.).
9. Kodama H., Fujisawa C. Copper metabolism and inherited copper transport disorders: molecular mechanisms, screening, and treatment. Metallomics 2009, 1:42-52.
10. Linder M.C, Wooten L., Cerveza P., Cotton S., Shulze R., Lomeli N. Copper transport. Am. J. Clin. Nutr. 1998, 67(5 Suppl.):965S-971S.
11. Crichton R.R., Wilmet S., Legssyer R., Ward R.J. Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J. Inorg. Biochem. 2002, 91(1):9-18.
12. Madsen E., Gitlin J.D. Copper and iron disorders of the brain. Annu. Rev. Neurosci. 2007, 30:317-337.
13. Barnham K.J., Bush A.I. Metals in Alzheimer's and Parkinson's diseases. Curr. Opin. Chem. Biol. 2008, 12(2):222-228.
14. Huang X., Moir R.D., Tanzi R.E., Bush A.I., Rogers J.T. Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann. NY Acad. Sci. 2004, 1012:153-163.
15. Gotz M.E, Double K., Gerlach M., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann. NY Acad. Sci. 2004, 1012:193-208.
16. Hayashi H., Yano M., Fujita Y., Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. Med. Mol. Morphol. 2006, 39(3):121-126.
17. Aaseth J., Flaten T.P., Andersen O. Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics. Scand. J. Gastroenterol. 2007, 42(6):673-681.
18. Mattson M.P Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann. NY Acad. Sci. 2004, 1012:37-50.
19. Letelier M.E., Lepe A.M., Faundez M., Salazar J., Marin R., Aracena P., Speisky H. Possible mechanisms underlying copper-induced damage in biological membranes leading to cellular toxicity. Chem. Biol. Interact. 2005, 151(2):71-82.
20. Letelier M.E., Faúndez M., Jara-Sandoval J., Molina-Berríos A., Cortés-Troncoso J., Aracena-Parks P., Marín-Catalán R. Mechanisms underlying the inhibition of the cytochrome P450 system by copper ions. J. Appl. Toxicol. 2010, 135(3):208-214.
21. Letelier M.E., Lagos F., Faundez M., Miranda D., Montoya M., Aracena-Parks P., Gonzalez-Lira V. Copper modifies liver microsomal UDP-glucuronyltransferase activity through different and opposite mechanisms. Chem. Biol. Interact. 2007, 167(1):1-11.
22. Letelier M.E., Martinez M., Gonzalez-Lira V., Faundez M., Aracena-Parks P. Inhibition of cytosolic glutathione S-transferase activity from rat liver by copper. Chem. Biol. Interact. 2006, 164(1-2):39-48.
23. Halliwell B., Gutteridge J.M. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990, 186:1-85.
24. Letelier M.E., Molina-Berrios A., Cortes-Troncoso J., Jara-Sandoval J., Müller A., Aracena-Parks P. Comparative effects of superoxide anion and hydrogen peroxide on microsomal and cytosolic glutathione S-transferase activities of rat liver. Biol. Trace Elem. Res. 2010, 134(1):203-211.
25. Aniya Y., Anders M.W. Activation of rat liver microsomal glutathione S-transferase by reduced oxygen species. J. Biol. Chem. 1989, 264(4):1998-2002.
26. Aniya Y., Anders M.W. Activation of rat liver microsomal glutathione S-transferase by hydrogen peroxide: role for protein-dimer formation. Arch. Biochem. Biophys. 1992, 296(2):611-616.
27. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193(1):265-275.
28. Letelier M.E., Pimentel A., Pino P., Lepe A.M., Faundez M., Aracena P., Speisky H. Microsomal UDP-glucuronyltransferase in rat liver: oxidative activation. Basic Clin. Pharmacol. Toxicol. 2005, 96(6):480-486.
29. Gaetke L.M., Chow C.K. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 2003, 189(1-2):147-163.
30. Altamura S, Muckenthaler M.U. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J. Alzheimers Dis. 2009, 16(4):879-895.
31. Gutteridge J.M., Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin. Haematol. 1989, 2(2):195-256.
32. Pinnen F., Cacciatore I., Cornacchia C., Sozio P., Cerasa L.S., Iannitelli A., Nasuti C., Cantalamessa F., Sekar D., Gabbianelli R., Falcioni M.L., Di Stefano A. Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease. J. Med. Chem. 2009, 52(2):559-563.
33. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., De Lorenzo A., Dinkova Kostova A.T., Calabrese V. Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs 2007, 16(12):1921-1931.
34. Crichton R.R., Ward R.J. Iron chelators and their therapeutic potential. Met. Ions Biol. Syst. 2004, 41:185-219.
35. Wang T., Guo Z. Copper in medicine: homeostasis, chelation therapy and antitumor drug design. Curr. Med. Chem. 2006, 13(5):525-537.